We review the literature concerning possible health risks for individuals (e.g. healthcare workers and pharmaceutical plant employees) occupationally exposed to cytostatic drugs.
Cytostatic drugs possess toxic properties and may therefore cause mutagenic, carcinogenic and teratogenic effects.
Hence, individuals handling these drugs in the course of their employment may face health risks.
For this reason, it is important to monitor occupational exposure to these drugs.
An overview of exposure monitoring methods is presented and their value is discussed.
Most studies involve nonselective methods for biological monitoring and biological effect monitoring, such as the urinary mutagenicity assay and analysis of chromosomal aberrations and sister-chromatid exchanges in peripheral blood lymphocytes.
The disadvantages of these biological methods are that their sensitivity is low and it cannot be proved beyond any doubt that the results found were caused by occupational exposure to cytostatic drugs.
For occupational health services it is important to have sensitive and specific methods for monitoring exposure to cytostatic drugs.
One of the most promising methods seems to be the determination of cyclophosphamide in urine using gas chromatographytandem mass spectrometry.
Several studies have demonstrated exposure to cyclophosphamide and other cytostatic drugs, even when protective measures were taken and safety guidelines were followed. (...)
Mots-clés Pascal : Exposition professionnelle, Mutagène, Article synthèse, Médecine travail, Cytostatique, Anticancéreux, Médicament, Personnel sanitaire, Teneur air ambiant, Lieu travail, Evaluation, Surveillance biologique, Toxicité, Activité biologique, Risque, Hôpital, Homme, Tumeur maligne, Carcinogène
Mots-clés Pascal anglais : Occupational exposure, Mutagen, Review, Occupational medicine, Cytostatic, Antineoplastic agent, Drug, Health staff, Ambient air concentration, Work place, Evaluation, Biological monitoring, Toxicity, Biological activity, Risk, Hospital, Human, Malignant tumor, Carcinogen
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0233306
Code Inist : 002B02U10. Création : 16/11/1999.